Published in Breast Care (Basel) on April 26, 2016
T-cell epitope strength in WAP-T mouse mammary carcinomas is an important determinant in PD1/PD-L1 immune checkpoint blockade therapy. Oncotarget (2016) 0.86
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? Int J Mol Sci (2017) 0.78
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) (2016) 0.78
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology (2017) 0.77
Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev (2016) 0.77
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. World J Clin Oncol (2017) 0.75
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. Onco Targets Ther (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54
Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 16.83
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med (2000) 13.13
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature (2014) 12.00
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med (2015) 10.12
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med (2014) 10.10
CTLA-4 can function as a negative regulator of T cell activation. Immunity (1994) 9.80
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res (2014) 8.11
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med (2009) 6.80
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med (1996) 6.13
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20
Neoantigens in cancer immunotherapy. Science (2015) 5.16
Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol (2013) 4.72
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol (2014) 4.27
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2011) 4.02
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature (2015) 3.86
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia (2006) 3.54
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol (2014) 3.15
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity (2013) 2.86
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity (2002) 2.71
In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res (2014) 2.68
Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat (2014) 2.61
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol (2012) 2.50
Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol (2013) 2.08
PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06
Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev (2014) 1.86
Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology (2014) 1.60
Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev (2014) 1.56
Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer (2007) 1.53
B7 family checkpoint regulators in immune regulation and disease. Trends Immunol (2013) 1.53
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48
PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PLoS One (2015) 1.45
Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res (2010) 1.42
Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol (2007) 1.35
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer (2016) 1.22
Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol (2015) 1.22
Update on metastatic gastric and esophageal cancers. J Clin Oncol (2015) 1.20
Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer. Clin Cancer Res (2015) 1.18
PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol (2015) 1.16
Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med (2011) 1.15
Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines (2010) 1.15
Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget (2015) 1.15
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res (2015) 1.15
Orchestrating immune check-point blockade for cancer immunotherapy in combinations. Curr Opin Immunol (2014) 1.10
CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2. Br J Cancer (2013) 1.06
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol (2015) 1.05
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol (2015) 1.03
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res (2010) 1.03
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. J Transl Med (2013) 1.02
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med (2011) 1.02
Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol (2015) 1.02
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. Semin Oncol (2015) 1.01
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res (2015) 1.01
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Res (2015) 0.98
High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget (2015) 0.98
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci (2015) 0.97
The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics (2012) 0.95
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies. Semin Oncol (2015) 0.95
Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol (2013) 0.94
The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol (2013) 0.90
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology (2016) 0.89
IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes. Br J Cancer (2013) 0.89
An inducible transgenic mouse breast cancer model for the analysis of tumor antigen specific CD8+ T-cell responses. Oncotarget (2015) 0.89
PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy. PLoS One (2015) 0.86
Emerging Co-signaling Networks in T Cell Immune Regulation. Immune Netw (2013) 0.86
Meta-analysis and metagenes: CXCL-13-driven signature as a robust marker of intratumoral immune response and predictor of breast cancer chemotherapeutic outcome. Oncoimmunology (2014) 0.85
Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother (2013) 0.84
Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clin Breast Cancer (2015) 0.84
Common pathways to tumor rejection. Ann N Y Acad Sci (2013) 0.83
Prognostic and predictive immune gene signatures in breast cancer. Curr Opin Oncol (2015) 0.83
Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opin Biol Ther (2014) 0.82
T cells and costimulation in cancer. Cancer J (2013) 0.81
Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Breast Cancer Res Treat (2015) 0.80
Adoptive immunotherapy of metastatic breast cancer: present and future. Cancer Metastasis Rev (2014) 0.79
Immunotherapy for breast cancer: is it feasible? Immunotherapy (2015) 0.79
Emerging immunotherapies in ovarian cancer. Discov Med (2015) 0.79
Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. Cancer Immunol Immunother (2015) 0.78
The immune-related role of BRAF in melanoma. Mol Oncol (2014) 0.78
Redox proteomics: Methods for the identification and enrichment of redox-modified proteins and their applications. Proteomics (2015) 0.83
Immunotherapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev (2017) 0.75